Policy

FTC Report Shows a Drop in Potentially Anticompetitive Drug Settlements

May 28th 2019

By The Center for Biosimilars Staff

A new Federal Trade Commission (FTC) staff report has found that, despite an increase in patent settlements concerning generic drugs, fewer settlements included the kinds of “pay-for-delay” provisions that are likely to be anticompetitive in nature.

British Columbia Becomes the First Canadian Province to Mandate a Switch to Biosimilars

May 28th 2019

By Kelly Davio

Officials in British Columbia announced on Monday that patients currently taking reference biologics for rheumatological diseases and diabetes will be switched to biosimilar products within 6 months.

Enzi, Hassan Introduce Bipartisan Bill to Improve Biosimilar Education

May 27th 2019

By Allison Inserro

Another piece of bipartisan legislation was introduced last week that seeks to promote biosimilars.

Colorado Becomes the First State to Cap Monthly Insulin Costs for Those With Insurance

May 24th 2019

By Allison Inserro

This week, Colorado Governor Jared Polis, D, signed the nation’s first bill that will cap insulin co-pays at $100 per month for people with health insurance.

Biosimilars Get a Boost in Senate's Sweeping Healthcare Package

May 24th 2019

By Kelly Davio

Yesterday, the Senate Committee on Health, Education, Labor, and Pensions released bipartisan draft legislation aimed at lowering the cost of healthcare in the United States.

The Top 5 Biosimilars Articles for the Week of May 20

May 24th 2019

The Center for Biosimilars® recaps the top news for the week of May 20, 2019.

What Can US Learn About Biosimilars From Europe?

May 24th 2019

By Allison Inserro

Europe has several lessons for the US biosimilar market, according to a pharmaceutical executive who spoke during ISPOR 2019.

Researchers Predict Substantial Savings for Europe on the Strength of Biosimilar Adalimumab

May 21st 2019

By Kelly Davio

During the ISPOR 2019 annual meeting, teams of investigators presented data estimating just how much healthcare systems could save by adopting biosimilar adalimumab for all indications of its reference in adult patients. The results highlighted both the scale of potential savings and the variability among European nations.

CMS Final Rule Expands Step Therapy to Part B, Makes Concessions on Protected Classes

May 20th 2019

By The Center for Biosimilars Staff

Last week, CMS issued a final rule that makes changes to Medicare Advantage and Medicare Parts D and B.

How Do Payers, PBMs Stack Up for Coverage of Autoimmune Disease Drugs?

May 16th 2019

By Allison Inserro

With the expanded use of step therapy on the horizon in 2020, an advocacy initiative of rheumatology, arthritis, and gastroenterology and other associations recently released a report “grading” payers and pharmacy benefit managers (PBMs) for the extent of their prescription coverage of medications for patients with autoimmune disorders.